Heart failure arises when the heart’s ability to pump blood around the body is impaired. This deprives the body’s tissues of the oxygen and nutrients upon which their survival depends. It commonly occurs as a result of conditions such as ischaemic heart disease, diabetes and high blood pressure.
Featured Learning Zones
Heart failure may be classified as being either acute or chronic. Acute heart failure is characterised by a sudden onset of symptoms, whereas in chronic heart failure typically develops and worsens over time.
Examples of the symptoms associated with heart failure include dyspnoea, fatigue, difficulty exercising, and oedema, particularly peripheral oedema. Symptoms may vary depending on which side or sides of the heart are affected.
Related news and insights
High-level results from the DELIVER Phase III trial showed AstraZeneca’s Farxiga (dapagliflozin) reached a statistically significant and clinically meaningful reduction in the primary composite endpoint of cardiovascular (CV) death or worsening heart failure (HF).
Nippon Boehringer Ingelheim’s SGLT2 inhibitor Jardiance (empagliflozin) has obtained a label update from PMDA in Japan allowing its use in patients with chronic heart failure with preserved ejection fraction (HFpEF) in addition to those with heart failure with reduced ejection fraction (HFrEF).